Sanofi(SNY) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

J.P. Morgan Sticks to Its Hold Rating for Sanofi (SNYNF)
TipRanks04:05 ET · Ratings
Sanofi's Tolebrutinib Granted FDA Priority Review For Non-Relapsing Secondary Progressive MS, Targeting Smoldering Neuroinflammation
Benzinga02:24 ET
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Sanofi (OtherSNYNF) and MacroGenics (MGNX)
TipRanks20:50 ET · Ratings
Press Release: Availability of the Q1 2025 Aide Mémoire
SanofiMar 24 00:00 ET
Notable Healthcare Headlines for the Week: Pfizer, Sanofi, Sarepta Therapeutics and Medtronic in Focus
Seeking AlphaMar 23 09:05 ET
Sanofi Initiated at Neutral at Goldman Sachs on Need to See Pipeline Successes
Seeking AlphaMar 21 13:31 ET

Comments

Teddy123

Mar 16 11:28

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

$Sanofi (SNY.US)$
Sanofi Leads Early Flu Vaccine Preparation as CDC Reports 40M Cases This Season

Moomoo Recap US

Dec 18, 2024 05:03

Columns Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today

The market fell Tuesday, but stepping back, the view of tech stocks looks like a mountain range that has not peaked yet- for all of December, the Nasdaq has arched upward into all-time highs. After Monday's record, the index pulled back, following a pullback for Nvidia and Broadcom, falling after Broadcom's post-earnings stock jump finally took a pause.
Just past 4 pm ET they $S&P 500 Index (.SPX.US)$ traded down 0.39%,...

16

3

10xStockPicks

Dec 16, 2024 08:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

11

2

4

Meltyy

Sep 25, 2024 19:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

9

1

Meltyy

Sep 10, 2024 17:37

📅 FDA PDUFA & AdCom Update…

📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...

5

1

SNY Sanofi

Trade Overview

Capital Trend

News

Comments

Market Insights